Redeye’s view on the Q4 report. The organic growth was weak, with large swings in the development in...
Redeye continues to be positive to Bredband2 following a Q4 report in line with our estimates, posti...
Redeye comments on Göran Forsberg leaving as CEO with Damian Marron from the board taking the role ...
Redeye comments on Alligator Bioscience's end of phase II meeting with the American regulatory autho...
Redeye returns following Elicera's Q4 report and recent news in the company.
Redeye comments on Tessin’s Q4 results, which were softer than expected.
EBIT SEK -28m vs. ABG SEK -25m — lower volumes Q1 likely better — no maintenance Conference call at ...
Sales +36% and EBIT +82% vs. ABGSCe Expect cons. to raise '25e-'26e sales by ~15% Overall a strong b...
Fiskars’ net sales continued the decreasing trend y/y in both Business Areas due to low consumer con...
Sales SEK 630m, -15% vs. ABGSCe EBIT of SEK 51m, -5% vs.
Redeye comments on I-Tech’s Q4 figures that significantly beat our estimates across the board, prima...
After a period of steady increase in both European Idefirix sales and patient usage, Hansa records a...
Redeye updates on Better Collective ahead of Q4-results (due February 19) where we expect a slight s...
Redeye is encouraged to see organic growth in the quarter after a relatively weak performance during...
Redeye continues to see a compelling long-term investment case.
Redeye initiates coverage of NextCell Pharma, a clinical-stage biotech company developing a cell the...
Q4 with meagre 5% organic growth and EBITDA 2% below But quite a few positives in the underlying ope...
Q4'24 results due 11 February '25e-'26e adj. EBIT revised by 0.
Hyresintäkterna steg med 38% till 12,4 meur och förvaltningsresultat ökade med 37% till 6,2 meur på ...
NOI +41% y-o-y and +1% vs ABGSCe Value uplift -0.3% q-o-q, net LTV at 52.
